Tg Therapeutics (TGTX) Cash from Financing Activities (2011 - 2026)

Tg Therapeutics' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $390.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 6504.93% year-over-year to $390.8 million; the TTM figure through Mar 2026 stood at $307.2 million (up 150.95% YoY), while the FY2025 annual figure was -$89.7 million, down 169.81% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $390.8 million, up from $1.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $390.8 million in Q1 2026, with the low at -$78.2 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $135000.0 (2022), against an average of $29.5 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 34749.63% in 2023, then tumbled 607100.0% in 2024.
• Tg Therapeutics' Cash from Financing Activities stood at $49000.0 in 2022, then sank by 102.04% to -$1000.0 in 2023, then sank by 607100.0% to -$6.1 million in 2024, then soared by 117.42% to $1.1 million in 2025, then jumped by 36840.36% to $390.8 million in 2026.
• Business Quant data shows TGTX's Cash from Financing Activities at $390.8 million in Q1 2026, $1.1 million in Q4 2025, and -$78.2 million in Q3 2025.